Compound Evidence File
#EC-2026-0747
Semaglutide Raw
Filed under Raw Materials. The bureau holds 102 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Jan 2026 | 19 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 10.0 | 10.0 | 18 Apr 2026 | 25 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Feb 2026 | 8 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Feb 2026 | 16 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 10.0 | 10.0 | 24 Mar 2026 | 14 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Nov 2025 | 10 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Feb 2026 | 25 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 9.9 | 14 Nov 2025 | 5 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 10.0 | 5 May 2026 | 10 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 9.9 | 14 Feb 2026 | 4 Jun 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 14 Jan 2026 | 20 Jan 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 22 Mar 2026 | 13 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 14 May 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 9.0 | 9.0 | 9.0 | 8 Jul 2025 | 8 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 8.6 | 7.8 | 9.6 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.6 | 8.1 | 9.0 | 23 May 2026 | 23 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.6 | 8.6 | 8.6 | 11 Jun 2025 | 11 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.2 | 7.0 | 8.8 | 24 May 2026 | 24 May 2026 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 8.2 | 8.2 | 8.2 | 24 Apr 2025 | 24 Apr 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.1 | 7.5 | 8.6 | 21 May 2026 | 21 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.0 | 6.8 | 9.5 | 24 May 2026 | 24 May 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 5 | 7.5 | 2.9 | 9.3 | 14 Jan 2025 | 17 May 2026 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 7.5 | 7.5 | 7.5 | 17 Dec 2024 | 17 Dec 2024 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 7.5 | 7.5 | 7.5 | 6 May 2025 | 6 May 2025 |
| Royal PeptidesCASE #VI-2026-0264 | X | 1 | 7.5 | 7.5 | 7.5 | 28 Mar 2025 | 28 Mar 2025 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 7.4 | 7.4 | 7.4 | 2 Jul 2025 | 2 Jul 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 2 | 7.0 | 6.8 | 7.3 | 9 Jun 2025 | 17 May 2026 |
| UtherCASE #VI-2026-0902 | X | 6 | 6.2 | 4.5 | 8.1 | 24 Apr 2025 | 26 Jan 2026 |
| LSPLCASE #VI-2026-0523 | X | 1 | 6.0 | 6.0 | 6.0 | 8 Jul 2025 | 8 Jul 2025 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 5.7 | 5.7 | 5.7 | 2 Apr 2025 | 2 Apr 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 2 | 5.0 | 3.9 | 6.2 | 21 May 2025 | 21 May 2026 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 3.8 | 3.8 | 3.8 | 21 May 2025 | 21 May 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 2.7 | 2.7 | 2.7 | 9 Jun 2025 | 9 Jun 2025 |
| Peptides For SaleCASE #VI-2026-0614 | X | 1 | 2.3 | 2.3 | 2.3 | 2 Apr 2025 | 2 Apr 2025 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 0.0 | 0.0 | 0.0 | 13 Jun 2025 | 13 Jun 2025 |
Open any subject to view the batch-level evidence for Semaglutide Raw alone.